DOCSLIB.ORG

III IIII US005506359A United States Patent 19 11 Patent Number: 5,506,359 Madras Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
III IIII US005506359A United States Patent 19 11 Patent Number: 5,506,359 Madras Et Al III IIII US005506359A United States Patent 19 11 Patent Number: 5,506,359 Madras et al. 45) Date of Patent: Apr. 9, 1996 (54) COCAINE ANALOGUES AND THEIR USE AS ne-Releasing Effects of H-3-CFT (WIN35,428): A Poten COCANE DRUG THERAPES AND tial Brain Imaging Ligand for Dopamine Transporter or THERAPEUTIC AND MAGNGAGENTS Cocaine . " Soc. Neuro. Abs., 16:309.5 (1990). FOR NEURODEGENERATIVE DISORDERS Clarke et al. "(2-exo-3-endo)-2-Aryltropane-3-carboxylic Esters, a (75) Inventors: Bertha K. Madras, Newton; Peter New Class of Narcotic Antagonists' J. Med. Chem, Meltzer, Lexington, both of Mass. 21:1235-1242 (1978). Clarke et al. "Compounds Affecting the Central Nervous 73) Assignee: President and Fellows of Harvard System. 4.3B-Phenyltropane-2-carboxylic Esters and Ana College, Cambridge, Mass. logs' J. Med. Chem., 16:1260-1267 (1973). Cline et al. "Behavior Effects of Novel Cocaine Analogs: A 21 Appl. No.: 111,141 Comparison with in Vivo Receptor Binding Potency' J. Pharm. & Exp. Therapeutics, 260:1174-1179 (1992). 22 Filed: Aug. 24, 1993 Daum et al. "Compounds Affecting the Central Nervous System. 3. 3?-Phenyltropan-2-ols' J. Med. Chem., Related U.S. Application Data 16:667-670 (1973). 63 Continuation-in-part of Ser. No. 934,362, Aug. 24, 1992, Elmaleh et al. “N-C-11 abandoned. -Methyl-2B-Carbomethoxy-3B-Phenyl Tropane C-11) PT) and Glucose Utilization in a Primate Model of Hun (51) Int. Cl. ...................................... CO7) 451/02 tington's Disease” J. Nuclear Med. Abs., 32:552 (1991). 52 U.S. Cl. ................. 546/130; 54.6/128; 54.6/129 Elmaleh et al. "Preparation and In Vivo Imaging of (58) Field of Search ..................................... 54.6/129, 130, N-C-11-Methyl-2-Carbomethoxy-3-Phenyl Tropane 54.6/128; 514/304 (IC-11 PT) in Monkey Brain' J. Nuclear Med. Abs., 32:1009 (1991). 56 References Cited Elmaleh et al. "PET Imaging Probes for the Cocaine Recep U.S. PATENT DOCUMENTS tors: A Walidation Study in a Nonhuman Primate Model' J. Nuclear Med. Abs., 33:946 (1992). 2,799,680 7/1957 Fromer ................................. 260f294.7 Goodman et al. "Radioiodinated 3,452,029 6/1969 Childress et al........................ 260/292 2B-Carbomethoxy-3B-(4-Chlorophenyl)-8-(3E-and 3,813,404 5/1974 Clarke et al. ........................... 260/292 3Z-Iodopropen-2-YL)Nortropanes: Synthesis of Potential 4,393,069 7/1983 Langbein et al........................ 424/265 Radioligands for Mapping Cocaine Receptor..." J. Nuclear 5,128,118 7/1992 Carroll et al. ........................... 424/1.1 Med. Abs., 33:890 (1992). OTHER PUBLICATIONS Hantraye et al. "Dopamine Fiber Detection by 'C-CFT and PET in a Primate Model of Parkinsonism' Clin. Neu Balster et al. "Potent Substituted-33-phenyltropane Ana rosci. and Neuropath., 3:265-268 (1992). logs of Cocaine have Cocaine-like Discriminative Stimulus Hillier “WIN-35,428" Drugs of the Future, 5:459-460 Effects' Drug and Alcohol Dependence, 29:145-151 (1991). (1980). Boja et al. "Isothiocyanate Derivatives of Cocaine: Irrevers Horn "Dopamine Uptake: A Review of Progress in the Last ible Inhibition of Ligand Binding at the Dopamine Trans Decade' Progress in Neurobiology, 34:387-400 (1990). porter' Molecular Pharmacology 39:339–345 (1991). Innis et al. "Single Photon Emission Tomography Imaging Boja et al. "New, Potent Cocaine Analogs: Ligand Binding of Monoamine Reuptake Sites in Primate Brain with 'I) and Transport Studies in Rat Striatum' European J. of CIT' Eur. J. of Pharmacol., 200:369-370 (1991). Pharmacology, 184:329-332 (1990). Kaufman et al. "Severe Depletion of Cocaine Recognition Brownell et al. "Glucose Utilization and N-C-11-Me Sites Associated With the Dopamine Transporter in thyl-2 Carbomethoxy-3-Phenyl Tropane (IC-11)PT) Stud Parkinson's-Diseased Striatum' Synapse, 9:43–49 (1991). ies of the Primate Model of Huntington's Disease” J. Kitayama et al. "Dopamine Transporter Site-Directed Muta Nuclear Med. Abs., 32:981 (1991). tions Differentially Alter Substrate Transport and Cocaine Canfield et al. "Autoradiographic Localization of Cocaine Binding” Proc. Natl. Acad. Sci., 89:7782-7785 (1992). Binding Sites by HCFT (HWIN35,428) in the Monkey Kline, Jr. et al. "Synthesis of 3-Arlecgonine Analogues as Brain" Synapse, 6:189-195 (1990). Inhibitors of Cocaine Binding and Dopamine Uptake” J. Carroll et al. "Probes for the Cocaine Receptor. Potentially Med. Chem., 33:2024-2027 (1990). Irreversible Ligands for the Dopamine Transporter'J. Med. Chem., 35:1813-1817 (1992). (List continued on next page.) Carroll et al. "Cocaine Receptor: Biochemical Characteriza tion and Structure-Activity Relationships of Cocaine Ana Primary Examiner-C. Warren Ivy logues at the Dopamine Transporter' J. Med. Chem., Assistant Examiner-Evelyn Huang 35:969-981 (1992). Attorney, Agent, or Firm-Fish & Richardson Carroll et al. "Synthesis, Ligand Binding, QSAR, and 57 ABSTRACT COMFA Study of 3B-(p-Substituted phenyl)tropane-2-carboxylic Acid Methyl Esters' J. Med. Disclosed are benztropine and CFT analogs useful for imag Chem., 34:2719-2725 (1991). ing of cocaine receptors and treatment of cocaine abuse. Carroll et al. "Synthesis and Ligand Binding of Cocaine Also disclosed are analogs useful for imaging and treatment Isomers at the Cocaine Receptor" J. Med. Chem., of Parkinson's disease. 34:883-886 (1991). Chen et al. "In Vivo Binding, Internalization, and Dopami 13 Claims, 18 Drawing Sheets 5,506,359 Page 2 OTHER PUBLICATIONS High-Affinity SPECT Radiotracer of Monoaminie Reuptake Leete "2-Carbomethoxy-3-tropinone: An Advanced Inter Sites in Brain' J. Med. Chem., 34:3144-3146 (1991). mediate in the Biosynthesis of Cocaine” J. Amer. Chem. Patel et al. "A Cocaine Analog and a GBR Analog Label the Soc., 83:6727-6728 (1983). Same Protein in Rat Striatal Membranes' Brain Res., Madras "'C-WIN 35.248 for Detecting Dopamine Deple 576:173-174 (1992). tion in Mild Parkinson's Disease' Annals of Neuro., Reith et al. "Radiolabeling of Dopamine Uptake Sites in 35:376-379 (1994). Mouse Striatum: Comparison of Binding Sites for Cocaine, Madras et al. "Stereoselective [3H]-Cocaine Binding to Mazindol, and GBR 12935' Arch. of Pharmacol., Membranes of Monkey Caudate-Putamen” Drug Abuse II 345:309-318 (1992). Abs., A197, Paper No. 135.9. Ritz et al. "Cocaine Inhibition of Ligand Binding at Dopam Madras et al. "N-Modified Fluorophenyltropane Analogs of ine, Norepinephrine and Serotonin Transporters: A Struc Cocaine With High Affinity for Cocaine Receptors' Phar ture-Activity Study' Life Sciences, 46:635-645 (1990). macol. Biochem. & Behav., 35:949-953 (1990). Madras et al. "HICFT: A Novel High Affinity Ligand for Rubenstein"III Imaging With Photons' Scientific American, Cocaine Receptors' Soc. for Neurosci. Abstracts, 15:803 1/88:1-14 (1988). (1989). Scheffel et al. "In Vivo Labeling of Cocaine Binding Sites on Madras et al. "Cocaine Receptors Labeled by 3H) Dopamine Transporters with H WIN 35.428" J. Pharma 2-Carbomethoxy-3f-(4-fluorophenyl)tropane” Molecu col. & Exper. Therapeutics, 257:954-958 (1991). lar Pharmacology, 36:518–524 (1989). Scheffel et al. "Cocaine Receptors: In Vivo Labeling With Madras et al. "3H)(-)-Cocaine Binding to Membranes of H-(-)Cocaine, H-WIN 35,065-2, and H-WIN 35,428” Monkey Striatum' FASEB J. Abstracts, 2:A1137 (1988). Synapse, 4:390-392 (1989). Meltzer et al. "Substituted 3-Phenyltropane Analogs of Spealman et al. "Self-Administration of the Cocaine: Synthesis, Inhibition of Binding at Cocaine Rec 2B-Carbomethoxy-3B(4-Fluorophenyl)Tropane' Pharma ognition Sites, and Position Emission Tomography Imag col. Biochem. & Behavior, 39:1011-1013 (1991). ing” J. Med. Chem., 36:855-862 (1993). Milius et al. "Synthesis and Receptor Binding of N-Substi Zakusov et al. "Pharmacology of New Tropan Derivatives' tuted Tropane Derivatives. High-Affinity Ligands for the Pharm. Ther., 32:327-337 (1987). Cocaine Receptor" J. Med. Chem., 34:1728-1731 (1991). Cutting W. C. in "The actions and uses of drugs. Handbook Milius et al., “[3H]-CFT, A High-Affinity Probe for the of Pharmacology. Appleton-Century-Crofts N.Y. 1969. Cocaine Receptor' Amer. Chem. Soc. Abstract, 199:1 Van der Zee et al., "A comparison of the inhibitory effects of (1990). aromatic substituted benzhydryl . into synaptosomal Neumeyer et al. “123) preparations of the rat brain”, Neuropharmacology, 17(7), -2B-Carbomethoxy-3B-(4-iodophenyl) tropane: 483-90, 1978. U.S. Patent Apr. 9, 1996 Sheet 1 of 18 5,506,359 H COCAINE ICso(moles/liter) 109 10:10 10:10 109 10-8 107 106 105 IC (moles/liter) CH CO2CH3 F HCFT H FIG. A H U.S. Patent Apr. 9, 1996 Sheet 2 of 18 5,506,359 CAUDATE-PUTAMEN 1000 00 10 RELATIVE POTENCY DOPAMINE UPTAKE OO OO O . 1 10 100 000 RELATIVE POTENCY HCFTBINDING FIG. 1B U.S. Patent Apr. 9, 1996 Sheet 3 of 18 5,506,359 I it it ly it in in i i if it it is NUCLEUS ACCUMBENS 1000 100 10 RELATIVE POTENCY DOPAMINEUPTAKE ms 001 001 01 1 10 100 1000 RELATIVE POTENCY HCFTBINDING FIG. 1C U.S. Patent Apr. 9, 1996 Sheet 4 of 18 5,506,359 OOO CAUDATE-PUAMEN 100 RELATIVE POTENCY STIMULANT EFFECT 0.1 0.01 0.01 0.1 1 10 100 1000 HCFTBINDING RELATIVE POTENCY FIG. 2A U.S. Patent Apr. 9, 1996 Sheet 5 of 18 5,506,359 000 CAUDATE-PUTAMEN 100 RELATIVE POTENCY SELF-ADMINISTRATION 1 0.1 0.01 0.01 0.1 1 10 100 1000 HCFTBINDING RELATIVE POTENCY FIG. 2B U.S. Patent Apr. 9, 1996 Sheet 6 of 18 5,506,359 HSWESIGSNOSN|XHwd[,] TOHINOOKONUDNU ENITESWEENITESWE TOC|N|ZWWHN|WOOO.. U.S. Patent Apr. 9, 1996 Sheet 7 of 18 5,506,359 FIG. 4a-A xxxx FIG. 4a-B rerorcorror FG. Aa-C - U.S.
Load more

Recommended publications
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Plant-Mediated Enantioselective Transformation of Indan-1-One and Indan-1-Ol. Part 2
    molecules Article Plant-Mediated Enantioselective Transformation of Indan-1-one and Indan-1-ol. Part 2 Wanda M ˛aczka 1,* , Katarzyna Wi ´nska 1,* , Małgorzata Grabarczyk 1,* and Renata Galek 2 1 Department of Chemistry, Wroclaw University of Environmental and Life Sciences, Norwida 25, 50-375 Wroclaw, Poland 2 Department of Genetics, Plant Breeding and Seed Production, Wroclaw University of Environmental and Life Sciences Pl. Grunwaldzki 24A, 53-363 Wroclaw, Poland; [email protected] * Correspondence: [email protected] (W.M.); [email protected] (K.W.); [email protected] (M.G.); Tel.: +48-71-320-5213 (W.M. & K.W.) Received: 31 October 2019; Accepted: 25 November 2019; Published: 27 November 2019 Abstract: The main purpose of this publication was to obtain the S-enantiomer of indan-1-ol with high enantiomeric excess and satisfactory yield. In our research, we used carrot callus cultures (Daucus carota L.), whereby the enzymatic system reduced indan-1-one and oxidized indan-1-ol. During the reaction of reduction, after five days, we received over 50% conversion, with the enantiomeric excess of the formed S-alcohol above 99%. In turn, during the oxidation of racemic indan-1-ol after 15 days, 36.7% of alcohol with an enantiomeric excess 57.4% S(+) remained in the reaction mixture. In addition, our research confirmed that the reactions of reduction and oxidation are competing reactions during the transformation of indan-1-ol and indan-1-one in carrot callus cultures. Keywords: indan-1-one; indan-1-ol; biotransformation; reduction; oxidation; carrot; callus culture 1.
    [Show full text]
  • 1St ANNUAL UNDERGRADUATE RESEARCH SYMPOSIUM
    Table of Contents Entree Subject Page 1 History of the Symposium 2 2 Program Schedule 4 3 Poster Abstract 28 4 Author/Faculty Information 132 5 Participating Institutions 137 1 HISTORY OF THE SYMPOSIUM Few activities are as rewarding as research to the motivated students as well as faculty mentors. In addition to the acquisition of invaluable research skills, students learn how knowledge is created and experience the excitement of the “eureka moment”. To celebrate undergraduate achievements, a research symposium has been held since 2007 on WPUNJ campus for students in biological and chemical sciences. In this event, undergraduate students present and display their research and creative work to the university and the scientific community from the Tri state area. This symposium provides an opportunity to the students to showcase their talents and share their research achievements with their peers from about twenty universities from Tri state area. The students and faculty from different universities as well as staff, and community members of WPU are invited to explore the latest in undergraduate research. Featured events include the poster presentation and Awards ceremony. The Symposium also features a keynote lecture by a distinguished researcher. 2 SYMPOSIUM ORGANIZING COMMITTEE Organizers Dr. Jaishri Menon Dr. Bhanu P. S. Chauhan Committee Members Dr. Jean Fuller-Stanley Dr. Michael Peek Dr. Eileen Gardner Dr. Jeung Woon Lee Dr. Carey Waldburger Dr. Pradeep Patnaik Dr. Mihaela Jitianu Dr. Mukesh Sahni Ms. Karyn Lapadura 3 SCHEDULE OF EVENTS 8:00 a.m. – 9:00 a.m. Registration & Breakfast Ballroom 9:00 a.m. – 9:15 am Welcome and Opening Remarks Dr.
    [Show full text]
  • Cocaine: Pharmacology, Effects, and Treatment of Abuse
    Cocaine: Pharmacology, Effects, and Treatment of Abuse U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Cocaine: Pharmacology, Effects, and Treatment of Abuse Editor: John Grabowski, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 50 1984 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY, COHEN M.D. Temple University School of Medicine LosAngeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic Institute National Federation of Parents for Troy, New York Drug Free Youth RICHARD BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTMAN Langley Porter Neuropsychiatric Institute San Francisco, California Alcohol and Drug Problems Association of North America Washington, D.C. DENISE KANDEL, Ph.D. GILBERT J. BOVTIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Cocaine in Seized Materials
    Recommended methods for the Identification and Analysis of Cocaine in Seized Materials MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits: UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Cocaine in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS New York, 2012 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases, but any modification has to be validated before it is integrated into laboratory routines. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. ST/NAR/7/REV.1 Original language: English © United Nations, March 2012. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. ii Contents Page 1. Introduction ................................................. 1 1.1 Background .............................................. 1 1.2 Purpose and use of the manual .............................. 1 2. Physical appearance and chemical characteristics of coca leaf and illicit materials containing cocaine ................................
    [Show full text]
  • Fate and Removal of Emerging Contaminants in Water and Wastewater Treatment Plants
    FATE AND REMOVAL OF EMERGING CONTAMINANTS IN WATER AND WASTEWATER TREATMENT PLANTS Faculty of Industrial Engineering Department of Civil, Constructional and Environmental Engineering Ph.D. School of Civil Engineering and Architecture Ph.D. Course in Environmental and Hydraulic Engineering - XXXII Cycle Ph.D. student Ing. Camilla Di Marcantonio Supervisor Co-Supervisor Prof. Agostina Chiavola Prof. Maria Rosaria Boni Abstract Abstract Organic MicroPollutants (OMPs) – also called Emerging Contaminants or Contaminants of Emerging Concern – include a wide number of chemicals belonging to different classes, e.g. pharmaceuticals and personal care products (PPCPs), drugs of abuse and their metabolites, steroids and hormones, endocrine- disrupting compounds, surfactants, perfluorinated compounds, phosphoric ester flame retardants, industrial additives and agents, siloxanes, artificial sweeteners, and gasoline additives (Barbosa et al., 2016; Bletsou et al., 2015; Chiavola et al., 2019). In the last two decades, increasing attention has been dedicated to OMPs, as a matter of high risk for public health and environment. (Naidu et al., 2016; Rodriguez-Narvaez et al., 2017; Thomaidi et al., 2016; Vilardi et al., 2017). OMPs are characterized by low environmental concentrations (about ng/L or µg/L), high toxicity, very low biodegradability and resistance to degradation and to conventional treatments. Consequently, they tend to be bioaccumulated in aquatic environments, and to enter the food chain through agriculture products and drinking water (Clarke and Smith, 2011). Measurement of OMPs in the aquatic medium became possible only in the last 20 years, thanks to the improvement of sensitivity and accuracy of the analytical methods; among the different methods, liquid chromatography coupled with high-resolution tandem mass spectrometry (LC-HRMS/MS) is increasingly applied for the analysis of some known and unknown emerging contaminants in water.
    [Show full text]
  • Screening Colour Test and Specific Colour Tests for the Detection of Methylendioxyamphetamine and Amphetamine Type Stimulants
    SCIENTIFIC AND TECHNICAL NOTES SCITEC 16 2009 Screening Colour Test and Specific Colour Tests for the Detection of Methylendioxyamphetamine and Amphetamine Type Stimulants Laboratory and Scientific Section, Division of Policy Analysis 1. Introduction The term amphetamine type stimulants (ATS) refer to a range of drugs mostly derived from the phenethylamines. Amphetamines are central nervous system (CNS) stimulants that were first synthesised more than a century ago for medical applications, but are currently mostly found on illicit drug markets. Globally, ATS use occurs in a range of contexts, and for a variety of purposes. Both recreational and occupational reasons may determine initial use; and use may occur in public settings (e.g., nightclubs), private parties, work environments or as sex aids. In this respect, ATS have demonstrated their attractiveness in a very wide range of situations that seem to differ across countries. ATS are used recreationally to experience the drug’s effects of increased sociability, loss of inhibitions, a sense of escape, or to enhance sexual encounters30‐34. In many high income countries, users typically have a history of other drug use and may use other substances in combination with M/A35‐38. M/A is sometimes used in occupational settings to sustain long work hours and to increase energy and productivity. Examples of this include use by jade‐mine workers in Myanmar, sex workers in Cambodia (Chouvy & Meissonnier, 2004), truck drivers73 159‐161 and even pilots in armed forces, where it has been provided by Governments (Emonson & Vanderbeek, 1995). Amphetamine (AMPT) and methamphetamine (MAMPT) both increase the release of dopamine, noradrenalin, adrenaline and serotonin (Seiden, Sobol, & Ricaurte, 1993; World Health Organization, 2004), stimulate the central nervous system, and have a range of effects including increased energy, feelings of euphoria, decreased appetite, elevated blood pressure and increased heart rate.
    [Show full text]
  • Nootropics- Memory Boosters
    Harikumar K. et al. / Journal of Pharmaceutical Biology, 6(1), 2016, 14-19. Journal of Pharmaceutical Biology www.jpbjournal.com e-ISSN - 2249-7560 Print ISSN - 2249-7579 NOOTROPICS- MEMORY BOOSTERS K.Hari Kumar*, Mitta Srija, D.K.Sandeep, Ramisetty Davarika, Gunda Sai Mounica Department of Pharmacology, Sri Venkateswara College of Pharmacy, R.V.S.Nagar, Chittoor-517127, Andhra Pradesh, India. ABSTRACT Nootropics also called as smart drug, memory enhancers, neuron enhancers, cognitive enhancers and intelligent enhancers are drugs, supplements, neutraceuticals and functional foods that provide one or more aspects of mental function. Specific effect can include improvement to working memory motivation or attention. Nootropics drugs are able to promote, enhance and protect cognitive functions. As cognition is the typically human higher activity of brain, nootropic concept looked quite appealing for scores of people dreaming to enjoy better and longer lasting mental activity and for drug maker keen to produce such enviable products. There are large number of drugs which can be used as nootropic agents and help to enhance memory of people. Nootropics offer lot of benefits for cognitive aptitude and brain health. Nootropics used for the treatment of Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, dementia and cognitive symptoms of schizophrenia. Keywords: Nootropics, Huntington’s disease, Dementia, Alzheimer’s disease. INTRODUCTION It is derived from Greek words “NOOS –Mind” But non-ADHD medications and supplements are more “Tropein – Turn/Bend”. They are also called as memory frequently used for performance enhancement. Many enhancers, Smart nutrients, Cerebroactive drugs and individuals use these drugs for performance enhancement cognition enhancers.
    [Show full text]
  • New Psychoactive Substances (NPS)
    New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34.
    [Show full text]
  • Staging Category Base Rate Article Description HS Heading/ Subheading D
    HS Heading/ SubheadingArticle description Base Rate Staging Category 280110000 - Chlorine 30% D 280120000 - Iodine 10% B 280130000 - Fluorine; bromine 5% A Sulphur, sublimed or precipitated; colloidal 280200000 sulphur. 5% A Carbon (carbon blacks and other forms of 280300000 carbon not elsewhere specified or included). 5% A 280410000 - Hydrogen 10% B 280421000 -- Argon 5% A 280429100 --- Neon 5% A 280429200 --- Helium 5% A 280429900 --- Other 10% B 280430000 - Nitrogen 30% D 280440000 - Oxygen : 30% D 280450000 - Boron; tellurium 10% B -- Containing by weight not less than 99.99 % of 280461000 silicon 10% B 280469000 -- Other 10% B 280470000 - Phosphorus 5% A 280480000 - Arsenic 10% B 280490000 - Selenium 5% A 280511000 -- Sodium 5% A 280519000 -- Other 5% A 280521000 -- Calcium 5% A 280522000 -- Strontium and barium 5% A - Rare-earth metals, scandium and yttrium, 280530000 whether or not intermixed or interalloyed 5% A 280540000 - Mercury 5% A 280610000 - Hydrogen chloride (hydrochloric acid) 30% D 280620000 - Chlorosulphuric acid 5% A 280700000 Sulphuric acid; oleum. 5% A 280800000 Nitric acid; sulphonitric acids. 5% A 280910000 - Diphosphorus pentaoxide 5% A 280920000 - Phosphoric acid and polyphosphoric acids 5% A 281000000 Oxides of boron; boric acids. 5% A 281111000 -- Hydrogen fluoride (hydrofluoric acid) 5% A 281119100 --- Hydrogen cyanide 5% A 281119900 --- Other 5% A 281121000 -- Carbon dioxide 30% D 281122000 -- Silicon dioxide 5% A 281123000 -- Sulphur dioxide 10% B 281129000 -- Other 5% A 281210100 -- Arsenic trichloride 5%
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]